When it comes to pot stocks the Cronos Group (NASDAQ:CRON) appears to have a different approach, but Cronos stock still is following the pot stock trend, and this is a problem.
Like all the marijuana stocks now crowding the market, its revenues, assets and cash flow bear no relation to the business it’s doing. It’s all speculation,
I once smoked pot, and on a recent Colorado vacation, I got the chance to see legal pot. This is not your father’s marijuana. It’s clean, it’s colorful, with no stems nor seeds that you don’t need, but it’s still marijuana. I didn’t get a legitimate dream for weeks after sitting in the second-hand smoke for an hour.
I know that’s not a normal symptom, but marijuana is not a normal substance. It’s complicated.
That’s what Cronos is trying to fix.
Lab Grown PotCronos is working to grow marijuana in a lab, using genetic engineering. It has a partnership with Gingko Bioworks, a Boston-based biotech firm, to transfer some cannabinoid DNA into yeast, and produce the product through fermentation.
Top 5 Biotech Stocks For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Cory Renauer]
If approved, Tegsedi will run directly into competition with Alnylam's (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven't been tested in a head-to-head study, but most analysts expect Alnylam's drug to gain a much larger share of the limited space than Akcea's.
- [By Motley Fool Staff]
Alnylam's (NASDAQ:ALNY) Onpattro is the first Food and Drug Administration (FDA)-approved RNAi therapy. However, competition is fast approaching and could make it difficult for Alnylam to pocket profits. Can Onpattro carve out significant sales as a treatment for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis?
- [By Cory Renauer]
Taking a medical breakthrough from concept through commercial success is like ascending a mountain that grows taller and more treacherous with every setback. It's taken Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) 16 years to launch its first drug, so challenges have had plenty of time to take up positions along this company's path to a successful first launch.
- [By Motley Fool Transcription]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
So, which biotech stocks should you consider buying in June? That's a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).
Top 5 Biotech Stocks For 2019: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Joseph Griffin]
ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.
Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.
- [By Maxx Chatsko]
Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Cory Renauer]
What's behind these dramatic gains? Read on to find out.
Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billionData source: YCharts.
Top 5 Biotech Stocks For 2019: Amgen Inc.(AMGN)
Advisors' Opinion:- [By ]
Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.
- [By Cory Renauer]
Lilly investors can also look forward to growing sales of the third new treatment for the prevention of migraine headaches. Emgality launched in October months after competing treatments from Amgen (NASDAQ:AMGN) and Teva Pharmaceuticals (NYSE:TEVA) late last year.
- [By Max Byerly]
Hammer Asset Management LLC purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,988 shares of the medical research company’s stock, valued at approximately $3,136,000. Amgen makes up 2.7% of Hammer Asset Management LLC’s holdings, making the stock its 13th largest holding.
- [By Logan Wallace]
Cantor Fitzgerald set a $223.00 price target on Amgen (NASDAQ:AMGN) in a research report sent to investors on Monday. The firm currently has a neutral rating on the medical research company’s stock.
- [By Keith Speights]
The big reason Humira will maintain its position at the top is the U.S. market. U.S. sales of the drug are projected to be around $12.2 billion in 2024. That's not much lower than Humira's 2017 U.S. sales of nearly $12.4 billion. Will Amgen's (NASDAQ:AMGN) biosimilar Amjevita, which will go on sale in the U.S. effective Jan. 31, 2023, really make that small of a dent in Humira's sales? Not really. The impact will be greater than the 2024 projections indicate.
- [By Ethan Ryder]
Wayne Hummer Investments L.L.C. trimmed its position in shares of Amgen (NASDAQ:AMGN) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,311 shares of the medical research company’s stock after selling 303 shares during the period. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $394,000 at the end of the most recent quarter.
Top 5 Biotech Stocks For 2019: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
As noted, the ability to take numerous swings for the fence makes Ionis special. It's often a marvel when a mid-cap drugmaker has a half-dozen experimental drugs, let alone one working with 25. Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ:BIIB), is one such drug that's put Ionis and its antisense technology on the map. Last year, Spinraza netted "just" $882 million in total sales, but delivered $364 million globally in the first quarter of 2018. That extrapolates out to more than $1.4 billion, which means added royalty revenue for Ionis.
- [By Joseph Griffin]
Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Benzinga News Desk]
A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link
ECONOMIC DATA Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week Personal Income Apr. Up 0.3%, Personal Spending Up 0.6% The Chicago PMI for May is schedule for release at 9:45 a.m. ET. The pending home sales index for April will be released at 10:00 a.m. ET. The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET. The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET. Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET. Fed Governor Lael Brainard will speak at 1:00 p.m. ET. Data on money supply for the recent week will be released at 4:30 p.m. ET. Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET. ANALYST RATINGS Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to NeutralThis is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.
No comments:
Post a Comment